ReviewBritish journal of clinical pharmacology2015
Role of biomarkers of nephrotoxic acute kidney injury in deliberate poisoning and envenomation in less developed countries.
Review in British journal of clinical pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 36 citations in OpenAlex.
- Melittin Nanoparticles Mitigate Glyphosate-Induced Nephrotoxicity via Cytokine Modulation and Bax/Nrf2 Pathways.Biomedicines · 2025Article
- Acute Kidney Failure among Brazilian Agricultural Workers: A Death-Certificate Case-Control Study.International journal of environmental research and public health · 2022Article
- Article
- Prevalence and Factors Associated with Acute Kidney Injury in Sub-Saharan African Adults: A Review of the Current Literature.International journal of nephrology · 2022Review
- Serum and urinary biomarkers for early detection of acute kidney injury following Hypnale spp. envenoming.PLoS neglected tropical diseases · 2021Article
- Urinary microRNAs as non-invasive biomarkers for toxic acute kidney injury in humans.Scientific reports · 2021Article
- MicroRNAs in toxic acute kidney injury: Systematic scoping review of the current status.Pharmacology research & perspectives · 2021Article
- Clinical assessment and pathophysiology ofThe journal of venomous animals and toxins including tropical diseases · 2020Article
- Thrombotic microangiopathy due to Bothrops erythromelas: a case report in Northeast Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2020Article
- Acute toxic kidney injury.Renal failure · 2019Review
- Paediatric poisoning in rural Sri Lanka: an epidemiological study.BMC public health · 2018Article
- Clinical Relevance and Predictive Value of Damage Biomarkers of Drug-Induced Kidney Injury.Drug safety · 2017Review
- Acute Kidney Injury Recognition in Low- and Middle-Income Countries.Kidney international reports · 2017Article
- Nephrotoxicity-induced proteinuria increases biomarker diagnostic thresholds in acute kidney injury.BMC nephrology · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) has diverse causes and is associated with increased mortality and morbidity. In less developed countries (LDC), nephrotoxic AKI (ToxAKI) is common and mainly due to deliberate ingestion of nephrotoxic pesticides, toxic plants or to snake envenomation. ToxAKI shares some pathophysiological pathways with the much more intensively studied ischaemic AKI, but in contrast to ischaemic AKI, most victims are young, previously healthy adults. Diagnosis of AKI is currently based on a rise in serum creatinine. However this may delay diagnosis because of the kinetics of creatinine. Baseline creatinine values are also rarely available in LDC. Novel renal injury biomarkers offer a way forward because they usually increase more rapidly in AKI and are normally regarded as absent or very low in concentration, thereby reducing the need for a baseline estimate. This should increase sensitivity and speed of diagnosis. Specificity should also be increased for urine biomarkers since many originate from the renal tubular epithelium. Earlier diagnosis of ToxAKI should allow earlier initiation of appropriate therapy. However, translation of novel biomarkers of ToxAKI into clinical practice requires better understanding of non-renal factors in poisoning that alter biomarkers and the influence of dose of nephrotoxin on biomarker performance. Further issues are establishing LDC population-based normal ranges and assessing sampling and analytical parameters for low resource settings. The potential role of renal biomarkers in exploring ToxAKI aetiologies for chronic kidney disease of unknown origin (CKDu) is a high research priority in LDC. Therefore, developing more sensitive biomarkers for early diagnosis of nephrotoxicity is a critical step to making progress against AKI and CKDu in the developing world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.